Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Oncol. 2014 Mar;8(2):273-84. doi: 10.1016/j.molonc.2013.11.008. Epub 2013 Dec 3.

The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen-receptor positive tumors.

Author information

1
Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, USA. Electronic address: dquigley@cc.ucsf.edu.
2
Breast Cancer Research Group, Nordic EMBL Partnership, Centre for Molecular Medicine Norway, (NCMM), University of Oslo, Norway. Electronic address: elisa.fiorito@ncmm.uio.no.
3
Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: silje.nord@rr-research.no.
4
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton UK; Department of Human Genetics, VIB and KU Leuven, Leuven, Belgium. Electronic address: pvl@sanger.ac.uk.
5
Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: Grethe.I.Grenaker.Alnas@rr-research.no.
6
Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: thofle@rr-research.no.
7
Laboratory for Functional Genomics, Fondation Jean Dausset, Centre Etude Polymorphism Humain, (CEPH), Paris, France; Laboratory of Epigenetics, Centre National de Génotypage, Commissariat à l'énergie Atomique et, aux énergies Alternatives (CEA)-Institut de Génomique, Evry, France. Electronic address: tost@cng.fr.
8
Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: Hans.Kristian.Moen.Vollan@rr-research.no.
9
Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: TRAMM@ONCOLOGY.DK.
10
Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: jens@oncology.dk.
11
Department of Breast-Endocrine Surgery, Akershus University Hospital, Oslo, Norway; Department of Oncology, Division of Cancer Medicine, Surgery and Transplantation, Oslo University Hospital, Oslo, Norway. Electronic address: i.r.k.bukholm@medisin.uio.no.
12
Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Breast Cancer Research Group, Nordic EMBL Partnership, Centre for Molecular Medicine Norway, (NCMM), University of Oslo, Norway. Electronic address: a.h.rodriguez@ncmm.uio.no.
13
Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, USA. Electronic address: abalmain@cc.ucsf.edu.
14
Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: a.l.borresen-dale@medisin.uio.no.
15
Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Clinical Molecular Biology (EpiGen), Medical Division, Akershus University Hospital, Lørenskog, Norway. Electronic address: Vessela.N.Kristensen@rr-research.no.

Abstract

Genome-wide association studies have identified numerous loci linked to breast cancer susceptibility, but the mechanism by which variations at these loci influence susceptibility is usually unknown. Some variants are only associated with particular clinical subtypes of breast cancer. Understanding how and why these variants influence subtype-specific cancer risk contributes to our understanding of cancer etiology. We conducted a genome-wide expression Quantitative Trait Locus (eQTL) study in a discovery set of 287 breast tumors and 97 normal mammary tissue samples and a replication set of 235 breast tumors. We found that the risk-associated allele of rs7716600 in the 5p12 estrogen receptor-positive (ER-positive) susceptibility locus was associated with elevated expression of the nearby gene MRPS30 exclusively in ER-positive tumors. We replicated this finding in 235 independent tumors. Further, we showed the rs7716600 risk genotype was associated with decreased MRPS30 promoter methylation exclusively in ER-positive breast tumors. In vitro studies in MCF-7 cells carrying the protective genotype showed that estrogen stimulation decreased MRPS30 promoter chromatin availability and mRNA levels. In contrast, in 600MPE cells carrying the risk genotype, estrogen increased MRPS30 expression and did not affect promoter availability. Our data suggest the 5p12 risk allele affects MRPS30 expression in estrogen-responsive tumor cells after tumor initiation by a mechanism affecting chromatin availability. These studies emphasize that the genetic architecture of breast cancer is context-specific, and integrated analysis of gene expression and chromatin remodeling in normal and tumor tissues will be required to explain the mechanisms of risk alleles.

KEYWORDS:

Breast cancer; Estrogen; Expression Quantitative Trait Locus; Genetics; chromatin

PMID:
24388359
PMCID:
PMC3964809
DOI:
10.1016/j.molonc.2013.11.008
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center